|
Near Final Draft of Checklist for Management
|
4
|
Resverlogix Corp.
|
Jul 26, 2016 04:18PM
|
|
NEJM Editorial on REDUCE-IT
|
3
|
Resverlogix Corp.
|
Nov 16, 2018 12:29PM
|
|
Neurotech Investing and Partnering Conference
|
2
|
BIOASIS TECHNOLOGIES INC
|
Apr 07, 2016 09:37PM
|
|
Never heard of them
|
4
|
BIOASIS TECHNOLOGIES INC
|
Sep 18, 2016 07:36AM
|
|
New Alkaline Phosphate publication from Dr. Kalantar-Zadeh
|
4
|
Resverlogix Corp.
|
Nov 17, 2019 10:00AM
|
|
New Apabetalone Clinical Trial for Pulmonary Arterial Hypertension
|
9
|
Resverlogix Corp.
|
Sep 03, 2018 11:34PM
|
|
New Apabetalone Fabry Disease Publication
|
9
|
Resverlogix Corp.
|
Apr 26, 2022 07:27AM
|
|
New Apabetalone Publication in Clinical Epigenetics
|
5
|
Resverlogix Corp.
|
Jul 12, 2019 05:04PM
|
|
New article on BET inhibition and renal disease
|
6
|
Resverlogix Corp.
|
Aug 02, 2016 05:17PM
|
|
New article on BET Inhibitors in Cardiovascular Disease
|
6
|
Resverlogix Corp.
|
Jan 30, 2019 01:22PM
|
|
New Blog Post-First of Three in Series on Complement System
|
4
|
Resverlogix Corp.
|
Oct 21, 2015 06:08PM
|
|
New Blog: Current Treatments for Complement Mediated Diseases
|
3
|
Resverlogix Corp.
|
Dec 22, 2015 02:57PM
|
|
New CEO Blog: Why biOasis Matters
|
|
BIOASIS TECHNOLOGIES INC
|
Dec 17, 2015 12:33PM
|
|
New content on Publications page of RVX website
|
4
|
Resverlogix Corp.
|
Jun 09, 2016 01:37PM
|
|
New Corporate Update Slide Deck
|
3
|
BIOASIS TECHNOLOGIES INC
|
Jun 11, 2019 11:29AM
|
|
New docs for Zenith in SEDAR 9/28/16
|
1
|
Zenith Epigenetics
|
Sep 28, 2016 08:27PM
|
|
New Fact Sheet
|
2
|
Resverlogix Corp.
|
Feb 01, 2019 06:51AM
|
|
New MD&A posted
|
6
|
Resverlogix Corp.
|
Dec 17, 2019 06:56AM
|
|
New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
3
|
Zenith Epigenetics
|
Mar 02, 2017 10:51AM
|
|
New publication
|
|
BIOASIS TECHNOLOGIES INC
|
May 04, 2018 05:25PM
|
